Material Information Sheet

Bicyclo[2.2.2]oct-7-ene-2,3,5,6-tetracarboxylic 2,3:5,6-diimide (BTI)

Material Information Sheet

Bicyclo[2.2.2]oct-7-ene-2,3:5,6-tetracarboxylic dianhydride (BTA)

Material Information Sheet

1,2,4,5-Cyclohexanetetracarboxylic 1,2:4,5-dianhydride (CHDA)

Material Information Sheet

1,2,4,5-Cyclohexanetetracarboxylic 1,2:4,5-diimide (CHDI)

Material Information Sheet

1,2,3,4,5,6-Cyclohexanehexacarboxylic 1,2:3,4:5,6-trianhydride (CHHA)

Material Information Sheet

Bicyclo[2.2.2]octane-2,3,5,6-tetracarboxylic 2,3:5,6-dianhydride (HBTA)

Material Information Sheet

Bicyclo[2.2.2]octane-2,3,5,6-tetracarboxylic 2,3:5,6-diimide (HBTI)

Material Information Sheet

N,N’-Bis(4-hydroxyphenyl)bicyclo[2,2,2]oct-7-ene-2,3,5,6-tetracarboxylic 2:3,5:6-diimide (BTA-PAP)

Material Information Sheet

N,N’-Bis(2-hydroxyethyl)bicyclo[2.2.2]oct-7-ene-2,3,5,6-tetracarboxylic 2:3,5:6-diimide (BODI)

New Catalogue product

APMN, 4-(4’-aminophenyl)-morpholin-3-one, the key intermediate for Rivaroxaban (2.5 mg), a worldwide produced blood thinner, is now part of our catalogue product portfolio. Valsynthese SA has recently launched a strategic investment in hydrogenation, of which APMN is one of the key products.

New Catalogue product

HBTA, Bicyclooctanetetracarboxylic dianhydride, a very promising key intermediate for electronic chemistry, is now part of our catalogue product portfolio. Valsynthese SA has recently launched a strategic investment in hydrogenation. HBTA is one of the key products.